Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cardiosphere-derived products.

Research focus: Treatment of heart disease associated with Duchenne.

Status: Phase 1/2 study.


Caprior announcement release

“Our research intends to halt cardiomyopathy progression in Duchenne which is a devastating complication that affects all most all those affected by the disease. We appreciate working with an innovative and forward-thinking organization like CureDuchenne that continues to fund impactful research to find treatments for Duchenne.”  — Dr. Linda Marbán, Chief Executive Officer of Capricor.

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.